Department of Botany, University of Rajasthan, Jaipur 302004, India.
J Ethnopharmacol. 2013 Aug 26;149(1):195-200. doi: 10.1016/j.jep.2013.06.022. Epub 2013 Jun 29.
Citrullus colocynthis (Cucurbitaceae), a folk herbal medicine and traditionally used natural remedy for tuberculosis in India has been studied to validate its antitubercular activity against drug sensitive and drug resistant (including multidrug resistant) Mycobacterium tuberculosis and Mycobacterium other than tuberculosis (MOTT) bacilli.
Inhibitory and bactericidal activities of crude extracts, fractions and compounds of Citrullus colocynthis plant, consisting of aerial parts and ripe deseeded fruits were performed against the drug sensitive standard strain of Mycobacterium tuberculosis H37Rv (ATCC 27294), 16 drug resistant strains of Mycobacterium tuberculosis and two MOTT strains, using radiometric BACTEC 460TB system.
Methanolic extract of ripe deseeded fruit of Citrullus colocynthis has shown good activity (MIC ≤ 62.5 µg/ml), whereas among the bioactive fractions, FC IX demonstrated the best activity (MIC 31.2 µg/ml) against Mycobacterium tuberculosis H37Rv. Bioactive FC III, IX and X also inhibited 16 clinical isolates of Mycobacterium tuberculosis consisting of seven non-multidrug resistants, eight multidrug resistants, one extensively drug resistant and two of MOTTs with MICs in the range of 50-125, 31.2-125 and 62.5-125 µg/ml, respectively. Ursolic acid and cucurbitacin E 2-0-β-d-glucopyranoside were identified as the main biomarkers active against Mycobacterium tuberculosis H37Rv (MICs 50 and 25 µg/ml respectively), as well as against the 18 clinical isolates. FC III and FC IX showed better inhibition of drug resistant and MOTT clinical isolates. Minimal bactericidal concentrations of extracts, fractions and compound C-2 were ≥ two-fold MIC values.
The study provides a scientific rationale for the traditional use of Citrullus colocynthis fruit in the treatment of tuberculosis. In addition, the study elucidates a broad spectrum antimycobacterial action of Citrullus colocynthis fruit, which can contribute to the development of improved preparation of an antitubercular natural drug for the treatment of drug resistant tuberculosis and MOTT infection as well.
刺山柑(葫芦科)是一种民间草药,也是印度传统的肺结核天然疗法,已被研究用于验证其对敏感和耐药(包括耐多药)结核分枝杆菌和非结核分枝杆菌(MOTT)杆菌的抗结核活性。
采用放射性 BACTEC 460TB 系统,对刺山柑植物的地上部分和成熟去籽果实的粗提取物、馏分和化合物,针对结核分枝杆菌 H37Rv(ATCC 27294)标准敏感株、16 株结核分枝杆菌耐药株和 2 株 MOTT 株进行了抑菌和杀菌活性检测。
刺山柑成熟去籽果实的甲醇提取物表现出良好的活性(MIC≤62.5μg/ml),而在生物活性馏分中,FCIX 表现出对结核分枝杆菌 H37Rv 的最佳活性(MIC31.2μg/ml)。生物活性 FCIII、IX 和 X 还抑制了由 7 株非耐多药、8 株耐多药、1 株广泛耐药和 2 株 MOTT 组成的 16 株临床分离株结核分枝杆菌,MIC 范围为 50-125μg/ml、31.2-125μg/ml 和 62.5-125μg/ml。熊果酸和葫芦素 E2-0-β-d-吡喃葡萄糖苷被鉴定为对结核分枝杆菌 H37Rv (MIC 分别为 50 和 25μg/ml)以及 18 株临床分离株具有活性的主要生物标志物。FCIII 和 FCIX 对耐药和 MOTT 临床分离株的抑制作用更好。提取物、馏分和化合物 C-2 的最低杀菌浓度(MBC)是 MIC 值的两倍以上。
该研究为刺山柑果实治疗肺结核的传统用途提供了科学依据。此外,该研究阐明了刺山柑果实广谱抗分枝杆菌活性,这有助于开发改进的抗结核天然药物制剂,用于治疗耐药性肺结核和 MOTT 感染。